Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Feb;45(2):375-380.
doi: 10.1007/s00264-020-04616-8. Epub 2020 May 23.

Effectiveness of a novel hydrolyzed collagen formulation in treating patients with symptomatic knee osteoarthritis: a multicentric retrospective clinical study

Piero Volpi  1 , Raul Zini  2 , Franz Erschbaumer  3 , Michelangelo Beggio  4 , Alberto Busilacchi  5 , Giulia Carimati  1
Affiliations

Effectiveness of a novel hydrolyzed collagen formulation in treating patients with symptomatic knee osteoarthritis: a multicentric retrospective clinical study

Piero Volpi et al. Int Orthop. 2021 Feb.

Abstract

Purpose: Knee osteoarthritis (OA) is a musculoskeletal disorder that may have a heavy impact on the patients' quality of life. Intra-articular collagen injection may be a safe adjuvant. Recently, CHondroGrid (CG), a hydrolyzed (< 3 kDa) bovine collagen injectable formulation, has been placed on the market. The aim of this study was to investigate the safety and performance profile of CG.

Methods: Patients affected by Kellgren Lawrence grade 1 to 4 knee OA and BMI < 30 were treated by administering three CG injections of 2 ml (4 mg) each (at 15 days and 45 days from the first one, respectively) and were followed up for six months after the last administration. Clinical records were retrospectively assessed to compare VAS, Lequesne and WOMAC total, pain, stiffness, and physical function scores collected at baseline and 15, 45, and 225 days after the first injection.

Results: At the last follow-up, 70 patients (37 men and 33 women, aged 57.1 ± 14.5 years) treated with CG showed a 50% reduction in their median Lequesne score, a 50% reduction in their VAS score at rest and moving, and a ≥ 50% reduction for all other scores under consideration.

Conclusions: CG may be a safe and effective adjuvant in the treatment of symptomatic knee OA.

Keywords: CHondroGrid; Intra-articular injection; Knee osteoarthritis; Non-pharmacological therapy.

PubMed Disclaimer

References

    1. Loeser RF, Collins JA, Diekman BO (2016) Ageing and the pathogenesis of osteoarthritis. Nat Rev Rheumatol 12:412–420. https://doi.org/10.1038/nrrheum.2016.65 - DOI - PubMed - PMC
    1. Martel-Pelletier J, Barr AJ, Cicuttini FM, Conaghan PG, Cooper C, Goldring MB, Goldring SR, Jones G, Teichtahl AJ, Pelletier JP (2016) Osteoarthritis. Nat Rev Dis Primers 2:16072. https://doi.org/10.1038/nrdp.2016.72 - DOI - PubMed
    1. Zhang Y, Jordan JM (2010) Epidemiology of osteoarthritis. Clin Geriatr Med 26(3):355–369. https://doi.org/10.1016/j.cger.2010.03.001 - DOI - PubMed - PMC
    1. Xie F, Kovic B, Jin X, He X, Wang M, Silvestre C (2016) Economic and humanistic burden of osteoarthritis: a systematic review of large sample studies. Pharmacoeconomics 34(11):1087–1100. https://doi.org/10.1007/s40273-016-0424-x - DOI - PubMed
    1. Cross M, Smith E, Hoy D et al (2014) The global burden of hip and knee osteoarthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis 73(7):1323–1330. https://doi.org/10.1136/annrheumdis-2013-204763 - DOI - PubMed - PMC

Substances

LinkOut - more resources